FDA grants F2G candidate drug olorofim breakthrough therapy
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, F2G(http://announced that the U.SFDA(http://awarded its first-candidate drug(http://olorofim breakthrough therapy for treatment of patients with invasive fungal infectionsOlorofim is the first antifungal drug to be identified as a breakthrough therapyF2G has discovered and developed a new antifungal agent called orotomides that selectively targets the fungal dihydrochheic dehydrogenase (DHODH)DHODH is a key enzyme in thepathway of the cephalogal bio
synthetic(http:// unlike the mechanisms of action of antifungal drugs already available on the market, and is lethal for a variety of rare and resistant fungal infectionsF2G's first candidate drug, olorofim (F901318), is a new class of DHODH inhibitors whose oral and intravenous preparations are currently in the early stages of clinical developmentPreviously, the EuropeanMedicines(http://Authority has granted olorofim orphan drug eligibility for the treatment of invasive clostridium and sporesThe breakthrough therapy was determined to be based on preliminary data from a Phase 2b clinicaltrial(http://Patients involved in the trial included patients with invasive fungal infections, patients with clostic disease, and patients with difficult-to-treat patients with poor response to existing antifungal infection medicationsOlorofim showed good tolerance in treatment, which lasted 12 weeks
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
